Assess whether to resubmit, meet, or pause the program from CMC comparability

SITUATION The working file is CMC comparability package for a site change after an inspector asking for batch records you cannot produce this week. Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal has to name To resubmit, meet, or Pause the program for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using CMC comparability package for a site change after an inspector asking for batch records you cannot produce this week.

HYPOTHESES TO TEST 1. The population in CMC comparability package for a site change is the one an inspector asking for batch records you cannot produce this week named, so To resubmit, meet, follows for this FDA Response and Labeling file. 2. The population in CMC comparability package for a site change is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the program is the honest Pharma & Life Sciences call. 3. A safety team sitting on a new disproportionate signal already contained an inspector asking for batch records you cannot produce this week before CMC comparability package for a site change arrived; no new FDA Response and Labeling path. 4. Provenance on CMC comparability package for a site change after an inspector asking for batch records you cannot produce this week is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 3. Check whether CMC comparability package for a site change supports the labeled claim pharmacovigilance medical reviewer would keep. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read CMC comparability package for a site change against an inspector asking for batch records you cannot produce this week and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (CMC comparability package for a site change after an inspector asking for batch records you cannot produce this week). The follow-on FDA Response and Labeling action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in CMC comparability package for a site change, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Regulatory or exam hook FDA Response and Labeling would cite - FDA Response and Labeling finding in CMC comparability package for a site change that a second reviewer can re-perform